ErbB receptors and epithelial-cadherin-catenin complex in human carcinomas

Future Oncology

Volumn 2, Issue 6, 2006, Pages 765-781

  Yasmeen, Amber ^a,b   Bismar, Tarek A ^a,b   Al Moustafa, Ala Eddin ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Epithelial cancer cells; Epithelial caderin catenin complex; ErbB receptors

Indexed keywords

ACTIN; CATENIN; CELL ADHESION MOLECULE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEFITINIB; PROTEIN TYROSINE KINASE; TRASTUZUMAB; UVOMORULIN;

ACTIN FILAMENT; BREAST CANCER; CANCER CELL; CANCER GROWTH; CARCINOMA; CELL ADHESION; CELL FUNCTION; CELL INTERACTION; EPITHELIUM CELL; EPITHELIUM TUMOR; EXTRACELLULAR MATRIX; HUMAN; LUNG NON SMALL CELL CANCER; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION;

CADHERINS; CARCINOMA; CATENINS; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; SIGNAL TRANSDUCTION;

EID: 33845688497     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.2.6.765     Document Type: Review

References (199)

1. Dikic I, Giordano S: Negative receptor signalling. Curr. Opin. Cell Biol. 15, 128-135 (2003).
2. Yarden Y, Sliwkowski MX: Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2, 127-137 (2001).
3. Sainsbury JR, Malcolm AJ, Appleton DR, Farndon JR, Harris AL: Presence of epidermal growth factor receptor as an indicator of poor prognosis in patients with breast cancer. J. Clin. Pathol. 38, 1225-1228 (1985).
4. Burgess AW, Cho HS, Eigenbrot C et al.: An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol. Cell 12, 541-552 (2003).
5. Gschwind A, Zwick E, Prenzel N, Leserer M, Ullrich A: Cell communication networks: epidermal growth factor receptor transactivation as the paradigm for interreceptor signal transmission. Oncogene 20, 1594-1600 (2001).
6. Hunter T, Eckhart W: The discovery of tyrosine phosphorylation: it's all in the buffer! CeLl 116, S35-S39 (2004).
7. Jorissen RN, Walker F, Pouliot N et al.: Epidermal growth factor receptor: mechanisms of activation and signalling. Exp. Cell Res. 284, 31-53 (2003).
8. Marmor MD, Skaria KB, Yarden Y. Signal transduction and oncogenesis by ErbB/HER receptors. Int. J. Radiat. Oncol. Biol. Phys. 58, 903-913 (2004).
9. Abud HE, Watson N, Heath JK: Growth of intestinal epithelium in organ culture is dependent on EGF signalling. Exp. Cell Res. 303, 252-262 (2005).
10. Ciccolini F, Mandl C, HoW-Wenig G, Kehlenbach A, Hellwig A: Prospective isolation of late development multipotent precursors whose migration is promoted by EGFR. Dev. Biol. 284,112-125 (2005).
11. Iwamoto R, Mekada E: ErbB and HB-EGF signaling in heart development and function. Cell Struct. Funct. 31, 1-14 (2006).
12. Stern DF: ErbBs in mammary development. Exp. Cell Res. 284, 89-98 (2003).
13. Harris RC, Chung E, Coffey RJ: EGF receptor ligands. Exp. Cell Res. 284,2-13 (2003).
14. Huang Y, Kim SO, Jiang J, Frank SJ: Growth hormone-induced phosphorylation of epidermal growth factor (EGF) receptor in 3T3-F442A cells. Modulation of EGF-induced trafficking and signaling. J. Biol. Chem. 278,18902-18913 (2003).
15. Wingens M, Wilma T, van Ingen H et al.: Structural analysis of an epidermal growth factor/transforming growth factor-α chimera with unique ErbB binding specificity. J. Biol. Chem. 278, 39114-39123 (2003).
16. Wouters MA. Rigoutsos I, Chu CK et al.: Evolution of distinct EGF domains with specific functions. Protein Sci. 14, 1091-1103 (2005).
17. Stortelers C, van De Poll ML, Lenferink AE et al.: Epidermal growth factor contains both positive and negative determinants for interaction with ErbB-2/ErbB-3 heterodimers. Biochemistry 41, 4292-4301 (2002).
18. Riese Dj 2nd, Stern DF: Specificity within the EGF Family/ErbB receptor family signaling network. Bioessays 20, 41-48 (1998).
19. Shelly M, Pinkas-Kramarski R, Guarino BC et al.: Epiregulin is a potent pan-ErbB ligand that preferentially activates heterodimeric receptor complexes. J. Biol. Chem. 273, 10496-10505(1998).
20. Falls DL: Neuregulins: functions, forms, and signaling strategies. Exp. Cell Res. 284, 14-30 (2003).
21. Holmes WE, Sliwkowski MX, Akita RW et al.: Identification of heregulin, a specific activator of p185erbB2. Science 256, 1205-1210 (1992).
22. Peles E, Bacus SS, Koski RA et al.: Isolation of the neu/HER-2 stimulatory ligand: a 44 kd glycoprotein that induces differentiation of mammary rumor cells. Cell 69, 205-216 (1992).
23. Wen D, Peles E, Cupples R et al.: Neu differentiation factor: a transmembrane glycoprotein containing an EGF domain and an inummoglobulin homology unit. Cell 69, 559-572 (1992).
24. Chang H, Riese DJ 2nd, Gilbert W, Stem DF, McMahan UJ: Ligands for ErbB-family receptors encoded by a neuregulin-like gene. Nature 387, 509-512 (1997).
25. Higashiyama S, Horikawa M, Yamada K et al. A novel brain-derived member of the epidermal growth factor family that interacts with ErbB3 and ErbB4. J Biochem. (Tokyo) 122,675-680 (1997).
26. Zhang D, Stiwkowski MX, Mark M et al.: Neuregulin-3 (NRG3): a novel neural tissue-enriched protein that binds and activates ErbB4. Proc. Natl Acad Sci. USA 94, 9562-9567(1997).
27. Harari D, Tzahar E, Romano J et al.: Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor tyrosine kinase. Oncogene 18, 2681-2689 (1999).
28. Kochupurakkal BS, Harari D, Di-Segni A et al.: Epigen, the last ligand of ErbB receptors, reveals intricate relationships between affinity and mitogenicity. J. Biol. Chem. 280, 8503-8512 (2005).
29. Strachan L, Murison JG, Prestidge RL et al.: Cloning and biological activity of epigen, a novel member of the epidermal growth factor superfamily. J. Biol. Chem. 276, 18265-18271(2001).
30. Uchida T, Wada K, Akamatsu T et al.: A novel epidermal growth factor-like molecule containing two follistatin modules stimulates tyrosine phosphorylation of ErbB-4 in MKN28 gastric cancer cells. Biochem. Biophys. Res. Commun. 266, 593-602 (1999).
31. Zhao XY, Schneider D, Biroc SL et al.: Targeting tomoregulin for radioimmunotherapy of prostate cancer. Cancer Res. 65, 2846-2853 (2005).
32. Paria BC, Elenius K, Klagsbrun M, Dey SK: Heparin-binding EGF-like growth factor interacts with mouse blastocysts independently of ErbB1: a possible role for heparan sulfate proteoglycans and ErbB4 in blastocyst implantation. Development 126, 1997-2005(1999).
33. Schroeder JA, Lee DC: Dynamic expression and activation of ERBB receptors in the developing mouse mammary gland. Cell Growth Differ. 9, 451-464 (1998).
34. Carteron C, Ferrer-Montiel A, Cabedo H: Characterization of a neural-specific splicing form of the human neuregulin 3 gene involved in oligodendrocyte survival. J. Cell Sci. 119, 898-909 (2006).
35. Olayioye MA, Neve RM, Lane HA, Hynes NE: The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 19, 3159-3167 (2000).
36. Ferguson KM, Berger MB, Mendrola JM et al.: EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Mol. Cell. 11, 507-517 (2003).
37. Garrett TP, McKern NM, Lou M et al.: The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol. Cell 11, 495-505 (2003).
38. Cho HS, Leahy DJ: Structure of the extracellular region of HER3 reveals an interdomain tether. Science 297, 1330-1333 (2002).
39. Bouyain S, Longo PA, Li S, Ferguson KM, Leahy DJ: The extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand. Proc. Natl Acad. Sci. VSA, 102, 15024-15029 (2005).
40. Benlimame N, He Q, Jie S et al.: FAK signaling is critical for ErbB-2/ ErbB-3 receptor cooperation for oncogenic transformation and invasion. J. Cell Biol. 171, 505-516 (2005).
41. Holbro T, Beerli RR, Maurer F et al.: The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc. Natl Acad, Sci. USA 100, 8933-8938 (2003).
42. Schlessinger J, Lemmon MA: SH2 and PTB domains in tyrosine kinase signaling. Sci. STKE 191, RE12 (2003).
43. Bagowski CP, Stein-Gerlach M, Choidas A, Ultrich A: Cell-type specific phosphorylation of threonines T654 and T669 by PKD defines the signal capacity of the EGF receptor. EMBO J 18, 5567-5576 (1999).
44. Biscardi JS, Tice DA, Parsons SJ: c-Src, receptor tyrosine kinases, and human cancer. Adv. Cancer Res. 76, 61-119 (1999).
45. Jones N, Dumont DJ: Recruitment of Dok-R to the EGF receptor through its PTB domain is required for attenuation of Erk MAP kinase activation. Curr. Biol. 9, 1057-1060 (1999).
46. Levkowitz G, Waterman H, Ettenberg SA et al.: Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol. Cell 4, 1029-1040 (1999).
47. Tice DA, Biscardi JS, Nickles AL, Parsons SJ: Mechanism of biological synergy between cellular Src and epidermal growth factor receptor. Proc. Natl Acad. Sci. USA 96, 1415-1420 (1999).
48. Alroy I, Soussan L, Seger R, Yarden Y: Neu differentiation factor stimulates phosphorylation and activation of the Sp1 transcription factor. Mol. Cell Biol. 19, 1961-1972 (1999).
49. Huang Y, Li X, Jiang J, Frank SJ: Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells. Oncogene (2006) (Epub ahead of print).
50. Jackson JG, Kreisberg JI, Koterba AP, Yee D, Brattain MG: Phosphorylation and nuclear exclusion of the forkhead transcription factor FKHR after epidermal growth factor treatment in human breast cancer cells. Oncogene 19, 4574-4581 (2000).
51. Mialon A, Sankinen M, Soderstrom H et al.: DNA topoisomerase I is a cofactor for c-jun in the regulation of epidermal growth factor receptor expression and cancer cell proliferation. Mol. Cell Biol. 25, 5040-5051 (2005).
52. O'Hagan RC, Hassell JA: The PEA3 Ets transcription factor is a downstream target of the HER2/Neu receptor tyrosine kinase. Oncogene 16, 301-310 (1998).
53. Olayioye MA, Beuvink I, Horsch K Daly JM, Hynes NE: ErbB receptor-induced activation of star transcription factors is mediated by Src tyrosine kinases. J. Biol. Chem. 274, 17209-17218 (1999).
54. Ramljak D, Coticchia CM, Nishanian TG et al.: Epidermal growth factor inhibition of c-Myc-mediated apoptosis through Akt and Erk involves Bcl-xL upregulation in mammary epithelial cells. Exp. Cell Res. 287, 397-410 (2003).
55. Zhou BP, Hu. MC, Miller SA et al.: HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-κB pathway. J. Biol. Chem. 275, 8027-8031 (2000).
56. Dankort D, Maslikowski B, Warner N et al.: Grb2 and Shc adapter proteins play distinct roles in Neu (ErbB-2)-induced mammary tumorigenesis: implications for human breast cancer. Mol. Cell Biol. 21, 1540-1551 (2001).
57. Maity A, Pore N, Lee J, Solomon D, O'Rourke DM: Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3-kinase and distinct from that induced by hypoxia. Cancer Res. 60, 5879-5886 (2000).
58. Elenius K, Choi CJ, Paul S et al.: Characterization of a naturally occurring ErbB4 isoform that does not bind or activate phosphatidyl inositol 3-kinase. Oncogene 18, 2607-2615 (1999).
59. Suenaga A, Takada N, Hatakeyama M et al.: Novel mechanism of interaction of p85 subunit of phosphatidylinositol 3-kinase and ErbB3 receptor-derived phosphotyrosyl peptides. J. Biol. Chem. 280, 1321-1326 (2005).
60. Mendelsohn J, Baselga J: The EGF receptor family as targets for cancer therapy. Oncogene 19, 6550-6565 (2000).
61. Halatsch ME, Schmidt U, Behnke-Mursch J, Unterberg A, Wirtz CR: Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours. Cancer Treat Rev. 32,74-89 (2006).
62. Lorimer IA: Mutant epidermal growth factor receptors as targets for cancer therapy. Curr. Cancer Drug Targets 2, 91-102 (2002).
63. Prenzel N, Zwick E, Daub H et al.: EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 402, 884-888 (1999).
64. Dong J, Opresko LB, Dempsey PJ et al.: Metalloprotease-mediated ligand release regulates autocrine signaling through the epidermal growth factor receptor. Proc. Natl Acad. Sci. 96, 6235-6240 (1999).
65. Izumi Y, Hirata M, Hasuwa H et al.: A metalloprotease-disintegrin, MDC9/ meltrin-γ/ADAM9 and PKCδ are involved in TPA-induced ectodomain shedding of membrane-anchored heparin-binding EGF-fike growth factor. EMBO J. 17, 7260-7272 (1998).
66. Yan Y, Shirakabe K, Werb Z: The metalloprotease Kuzbanian (ADAM10) mediates the transactivation of EGF receptor by G protein-coupled receptors. J. Cell Biol. 158, 221-226 (2002).
67. Sternlicht MD, Sunnarborg SW, Kouros-Mehr H et al.: Mammary ductal morphogenesis requires paracrine activation of stromal EGFR via ADAM17-dependent shedding of epithelial amphiregulin. Development 132, 3923-3933 (2005).
68. Hart S, Fischer OM, Prenzel N et al.: GPCR-induced migration of breast carcinoma cells depends on both EGFR signal transactivation and EGFR-independent pathways. Biol. Chem. 386, 845-855 (2005).
69. Civenni G, Holbro T, Hynes NE: Wnt1 and Wnt5a induce cyclin D1 expression through ErbB1 transactivation in HC11 mammary epithelia] cells. EMBO Rep. 4,166-171 (2003).
70. Sebastian S, Settleman J, Reshkin SJ et al: The complexity of targeting EGFR signalling in cancer: from expression to turnover. Biochim. Biophys. Acta 1766, 120-139 (2006).
71. Cohen MH, Williams GA, Sridhara R et al.: United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; lressa®) tablets. Clin. Cancer Res. 10, 1212-1218 (2004).
72. Lynch TJ, Bell DW, Sordella R et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129-2139 (2004).
73. Paez JG, Janne PA, Lee JC et al.: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497-1500 (2004).
74. Marchetti A, Martella C, Felicioni L et al.: EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J. Clin. Oncol. 23, 857-865 (2005).
75. Blencke S, Zech B, Engkvist O et al.: Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors. Chem. Biol, 11, 691-701 (2004).
76. Pao W, Miller V, Zakowski M et al.: EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl Acad. Sci. USA 101, 13306-13311 (2004).
77. Pao W. Miller VA, Politi KA et al.: Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2, E73 (2005).
78. Way TD, Lin JK: Role of HER2/HER3 co-receptor in breast carcinogenesis. Future Oncol, 1, 841-849 (2005).
79. Eccles SA: The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis. J. Mammary Gland Biol. Neoplasia 6, 393-406 (2001).
80. Slamon DJ, Clark GM, Wong SG et al.: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177-182 (1987).
81. Nunes RA, Harris LN: The HER2 extracellular domain as a prognostic and predictive factor in breast cancer. Clin. Breast Cancer 3, 125-137 (2002).
82. Kauraniemi P, Kallioniemi A: Activation of multiple cancer-associated genes at the ERBB2 amplicon in breast cancer. Endocr. Relat. Cancer 13, 39-49 (2006).
83. Kauraniemi P, Kuukasjarvi T, Sauter G, Kallioniemi A: Amplification of a 280-kilobase core region at the ERBB2 locus leads to activation of two hypothetical proteins in breast cancer. Am. J. Pathol. 163, 1979-1984 (2003).
84. Luoh SW: Amplification and expression of genes from the 17q11 approximately q12 amplicon in breast cancer cells. Cancer Genet. Cytogenet. 136, 43-47 (2002).
85. Kuwada SK,Kuang J, Li X: Integrin α5/β1 expression mediates HER-2 down-regulation in colon cancer cells. J. Biol. Chem. 280, 19027-19035 (2005).
86. Puputti M, Silito H, Isola J et al.: Allelic imbalance of HER2 variant in sporadic breast and ovarian cancer. Cancer Genet. Cytogenet. 167, 32-38 (2006).
87. Scholl S, Beuzeboc P, Pouillart P: Targeting HER2 in other tumor types. Ann. Oncol. 12(Suppl. 1), S81-S87 (2001).
88. Lane HA, Beuvink I, Motoyama AB et al.: ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency. Mol Cell Biol. 20, 3210-3223 (2000).
89. Neve RM, Sutterluty H, Pullen N et al.: Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells. Oncogene 19, 1647-1656 (2000).
90. Shin I, Yakes FM, Rojo F et al.: PKB/Akr mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization. Nat. Med. 8, 1145-1152 (2002).
91. Yang HY, Zhou BP, Hung MC, Lee MH: Oncogenic signals of HER-2/neu in regulating the stability of the cyclin-dependent kinase inhibitor p27. J Biol Chem. 275, 24735-24739 (2000).
92. Neve RM, Holbro T, Hynes NE: Distinct roles for phosphoinositide 3-kinase, mitogen-activated protein kinase and p38 MAPK in mediating cell cycle progression of breast cancer cells. Oncogene 21, 4567-4576 (2002).
93. Motoyama AB, Hynes NE, Lane HA: The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides. Cancer Res. 62, 3151-3158 (2002).
94. Yakes FM, Chinratanalab W, Ritter CA et al.: Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res. 62, 4132-4141 (2002).
95. Normanno N, De Luca A, Bianco C et al.: Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366, 2-16 (2006).
96. Alimandi M, Romano A, Curia MC et al.: Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene 10, 1813-1821 (1995).
97. Renshaw MW, Price LS, Schwartz MA: Focal adhesion kinase mediates the integrin signaling requirement for growth factor activation of MAP kinase. J. Cell Biol. 147, 611-618 (1999).
98. Schlaepfer DD, Jones KC, Hunter T: Multiple Grb2-mediated integrin-stimulated signaling pathways to ERK2/mitogen-activated protein kinase: summation of both c-Src- and focal adhesion kinase-initiated tyrosine phosphorylation events. Mol. Cell Biol. 18, 2571-2585 (1998).
99. Gullick WJ, Srinivasan R: The type 1 growth factor receptor family: new ligands and receptors and their role in breast cancer. Breast Cancer Res. Treat. 52, 43-53 (1998).
100. Srinivasan R, Poulsom R, Hurst HC, Gullick WJ: Expression of the c-erbB-4/HER4 protein and mRNA in normal human fetal and adult tissues and in a survey of nine solid turnout types. J. Pathol 185, 236-245 (1998).
101. Plowman GD, Culouscou JM, Whitney GS et al.: Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family. Proc. Natl Acad. Sci. USA 90,1746-1750 (1993).
102. Knowlden JM, Gee JM, Seery LT et al: c-erbB3 and c-erbB4 expression is a feature of the endocrine responsive phenotype in clinical breast cancer. Oncogene 17, 1949-1957 (1998).
103. Pawlowski V, Revillion F, Hebbar M, Hornez L, Peyrat JP: Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay. Clin. Cancer Res. 6, 4217-4225 (2000).
104. Suo Z, Berner HS, Risberg B, Karlsson MG, Nesland JM: Estrogen receptor-α and C-ERBB-4 expression in breast carcinomas. Virchows Arch. 439, 62-69 (2001).
105. Kew TY, Bell JA, Pinder SE et al.: c-erbB-4 protein expression in human breast cancer. Br. J. Cancer 82, 1163-1170 (2000).
106. Srinivasan R, Gillett CE, Barnes DM, Gullick WJ: Nuclear expression of the c-erbB-4/HER-4 growth factor receptor in invasive breast cancers. Cancer Res. 60, 1483-1487 (2000).
107. Lodge AJ, Anderson JJ, Gullick WJ et al.: Type 1 growth factor receptor expression in node positive breast cancer: adverse prognostic significance of c-erbB-4. J. Clin. Pathol. 56, 300-304 (2003).
108. Soung YH, Lee JW, Kim SY et al.: Somatic mutations of the ERBB4 kinase domain in human cancers. Int. J. Cancer 118, 1426-1429 (2006).
109. Al Moustafa AE, Alaoui-Jarnali M, Paterson J, O'Connor-McCourt M: Expression of P185erbB-2, P160erbB-3, P180erbBA and heregulin-α in human normal bronchial epithelial and lung cancer cell lines. Anticancer Res. 19, 481-486 (1999).
110. Gilbertson R, Hernan R, Pietsch T et al.: Novel ERBB4 juxtamembrane splice variants are frequently expressed in childhood medulloblastoma. Genes Chromosomes Cancer 31, 288-294 (2001).
111. Gullick WJ: c-erbB-4/HER4: friend or foe? J. Pathol 200,279-281 (2003).
112. Penington DJ, Bryant I, Riese DJ 2nd: Constitutively active ErbB4 and ErbB2 mutants exhibit distinct biological activities. Cell Growth Differ. 13, 247-256 (2002).
113. Yumoto N, Yu X, Hatakeyama M: Expression of the ErbB4 receptor causes reversal regulation of PP2A in the Shc signal transcluction pathway in human cancer cells. Mol. Cell Biochem. 285, 165-171 (2006).
114. Carpenter G: ErbB-4: mechanism of action and biology. Exp. Cell Res. 284, 66-77 (2003).
115. Cheng QC, Tikhomirov O, Zhou W, Carpenter G: Ectodomain cleavage of ErbB-4: characterization of the cleavage site and m80 fragment. J. Biol. Chem. 278, 38421-38427 (2003).
116. Gumbiner BM: Regulation of cadherin-mediated adhesion in morphogenesis. Nat. Rev. Mol. Cell Biol., 6, 622-634 (2005).
117. Yap AS, Brieher WM, Gumbiner BM: Molecular and functional analysis of cadherin-based adherens junctions. Ann. Rev. Cell Dev. Biol. 13, 119-146 (1997).
118. Yagi T, Takeichi M: Cadherin superfamily genes: functions, genomic organization, and neurologic diversity. Genes Dev. 14, 1169-1180 (2000).
119. Pappas DJ, Rimin DL: Direct interaction of the C-terminal domain of α-catenin and F-actin is necessary for stabilized cell-cell adhesion. Cell Commun. Adhes. 13, 151-170 (2006).
120. Weiss EE, Kroernker M, Rudiger AH, Jockusch BM, Rudiger M: Vinculin is part of the cadherin-catenin junctional complex: complex formation between α-catenin and vinculin.J. Cell Biol. 141, 755-764 (1998).
121. Bullions LC, Levine AJ: The role of β-catenin in cell adhesion, signal transduction, and cancer. Curr. Opin. Oncol. 10, 81-87 (1998).
122. Polakis P: Writ signaling and cancer. Genes Dev. 14, 1837-1851 (2000).
123. Gradl D, Kuhl M, Vedhch D: The Wnt/Wg signal transducer β-catenin controls fibronectin expression. Mol. Cell Biol. 19, 5576-5587 (1999).
124. Thomas GM, Frame S, Goedert M et al.: A GSK3-binding peptide from FRAT1 selectively inhibits the GSK3-catalysed phosphorylation of axin and β-catenin. FEBS Lett. 458, 247-251 (1999).
125. Polakis P: The oncogenic activation of P-catenin. Curr. Opin. Genet. Dev. 9, 15-21 (1999).
126. Hamada F, Bienz M: A Drosophila APC tumour suppressor homologue functions in cellular adhesion. Nat. Cell Biol. 4, 208-213 (2002).
127. Lin SY, Xia W, Wang JC et al.: β-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc. Natl Acad. Sci. USA 97, 4262-4266 (2000).
128. Yu X, Waltzer L, Bienz M: A new Drosopbila APC homologue associated with adhesive zones of epithelial cells. Nat. Cell Biol. 1, 144-151 (1999).
129. Mann B, Gelos M, Siedow A et al.: Target genes of β-catenin T-cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas. Proc. Natl Acad. Sci. USA 96,1603-1608 (1999).
130. Hovanes K, Li TW, Munguia JE et al.: β-catenin-sensitive isoforms of lymphoid enhancer factor- 1 are selectively expressed in colon cancer. Nat. Genet. 28, 53-57 (2001).
131. Koh TJ, Bulitta CJ, Fleming JV et al.: Gastrin is a target of the β-catenin/TCF-4 growth-signaling pathway in a model of intestinal polyposis. J Clin. Invest. 106, 533-539(2000).
132. Shtutman M, Zhurinsky J, Simcha I et al.: The cyclin D1 gene is a target of the β-catenin/LEF-1 pathway. Proc. Natl Acad Sci. USA 96, 5522-5527 (1999).
133. Takahashi M, Tsunoda T, Seiki M, Nakamura Y, Furukawa Y: Identification of membrane-type matrix metalloproteinase-1 as a target of the Β-catenin/Tcf4 complex in human colorectal cancers. Oncogene 21, 5861-5867 (2002).
134. Tetsu O, McCormick F: β-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398, 422-426 (1999).
135. Vleminckx K, Kemler R: Cadherins and tissue formation: integrating adhesion and signaling. Bioessays 21, 211-220 (1999).
136. Rowlands TM, Symonds JM, Farookhi R, Blaschuk OW. Cadherins: crucial regulators of structure and function in reproductive tissues. Rev. Reprod. 5, 53-61 (2000).
137. Christofori G, Semb H: The role of the cell-adhesion molecule E-cadherin as a tumour-suppressor gene. Trends Biochem. Sci. 24, 73-76 (1999).
138. Hajra KM, Fearon ER. Cadherin and catenin alterations in human cancer. Genes Chromosomes Cancer 34, 255-268 (2002).
139. D'Souza-Schorey C: Disassembling adherens junctions: breaking up is hard to do. Trends Cell Biol. 15, 19-26 (2005).
140. Sudo M, Chong JM, Sakuma K et al.: Promoter hypermethylation of E-cadherin and its abnormal expression in Epstein-Barr virus-associated gastric carcinoma. Int. J. Cancer 109, 194-199 (2004).
141. Berx G, Becker KF, Hofler H, van Roy F: Mutations of the human E-cadherin (CDH1) gene. Hum. Mutat. 12,226-237 (1998).
142. Machado JC, Oliveira C, Carvalho R et al.: F-cadherin gene (CDH1) promoter methylation as the second hit in sporadic diffuse gastric carcinoma. Oncogene 20, 1525-1528 (2001).
143. Hirohashi S: Inactivation of the E-cadherin-mediated cell adhesion system in human cancers. Am. J Pathol. 153, 333-339 (1998).
144. Batlle E, Sancho E, Franci C et al.: The transcription factor snail is a repressor of E-cadherin gene expression in epithelial rumour cells. Nat. Cell Biol. 2, 84-89 (2000).
145. Cano A, Perez-Moreno MA, Rodrigo I et al.: The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat. Cell Biol. 2, 76-83 (2000).
146. Comijn J, Berx G, Vermassen P et al.: The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. Mol. Cell 7, 1267-1278 (2001).
147. Poser I, Dominguez D, de Herreros AG et al.: Loss of E-cadherin expression in melanoma cells involves up-regulation of the transcriptional repressor Snail. J. Biol. Chem. 276, 24661-24666 (2001).
148. Yokoyama K, Kamata N, Hayashi E et al.: Reverse correlation of E-cadherin and snail expression in oral squamous cell carcinoma cells in vitro. Oral Oncol 37, 65-71 (2001).
149. Batlle E, Henderson JT, Beghtel H et al.: β-catenin and TCF mediate cell positioning in the intestinal epithelium by controlling the expression of EphB/ephrinB. Cell 111, 251-263 (2002).
150. Bolos V, Peinado H, Perez-Moreno MA et al.: The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors. J Cell Sci. 116,499-511 (2003).
151. Grooteclaes ML, Frisch SM: Evidence for a function of CtBP in epithelial gene regulation and anoikis. Oncogene 19, 3823-3828 (2000).
152. Nieto MA: The snail superfamily of zinc-finger transcription factors. Nat. Rev. Mol. Cell Biol. 3,155-166 (2002).
153. Perez-Moreno MA, Locascio A, Rodrigo I et al.: A new role for E12/E47 in the repression of E-cadherin expression and epithelial-mesenchymal transitions. J. Biol. Chem. 276, 27424-27431 (2001).
154. Yokoyama K, Kamata N, Fujimoto R et al.: Increased invasion and matrix metalloproteinase-2 expression by Snail-induced mesenchymal transition in squamous cell carcinomas. Int. J. Oncol. 22, 891-898 (2003).
155. Hlubek F, Jung A, Korzor N, Kirchner T, Brabletz T: Expression of the invasion factor laminin γ2 in colorectal carcinomas is regulated by β-catenin. Cancer Res. 61, 8089-8093 (2001).
156. Wielenga VJ, Smits R, Korinek V et al.: Expression of CD44 in Apc and Tcf mutant mice implies regulation by die WNT pathway. Am. J. Pathol. 154, 515-523 (1999).
157. Barker N, Clevers H: Tumor environment: a potent driving force in colorectal cancer? Trends Mol. Med. 7, 535-537 (2001).
158. Brabletz T, Jung A, Reu S et al: Variable β-catenin expression in colorectal cancers indicates tumor progression driven by the minor environment. Proc. Natl Acad. Sci. USA 98, 10356-10361 (2001).
159. Davies BR, Worsley SD, Ponder BA: Expression of E-cadherin, α-catenin and β-catenin in normal ovarian surface epithelium and epithelial ovarian cancers. Histopathology 32, 69-80 (1998).
160. Nakanishi Y, Ochiai A, Akimoto S et al.: Expression of E-cadherin, α-catenin, β-catenin and plakoglobin in esophageal carcinomas and its prognostic significance: immunohistochemical analysis of 96 lesions. Oncology 54, 158-165 (1997).
161. Lecuir T: Adhesion remodeling underlying tissue morphogenesis. Trends Cell Biol. 15, 34-42 (2005).
162. Conacci-Sorrell M, Zhurinsky J, Ben-Ze'ev A: The cadherin-catenin adhesion system in signaling and cancer. J. Clin. Invest. 109, 987-991 (2002).
163. Fuchs M, Hutzler P, Handschuh G et al.: Dynamics of cell adhesion and motility in living cells is altered by a single amino acid change in E-cadherin fused to enhanced green fluorescent protein. Cell Motil. Cytoskeleton 59, 50-61 (2004).
164. Holbro T, Civenni G, Hynes NE: The ErbB receptors and their role in cancer progression. Exp. Cell Res. 284, 99-110 (2003).
165. Lit Z, Ghosh S, Wang Z, Hunter T: Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of β-catenin, and enhanced tumor cell invasion. Cancer Cell 4, 499-515 (2003).
166. Seton-Rogers SE, Lu Y, Hines LM et al.: Cooperation of the EfbB2 receptor and transforming growth factor-β in induction of migration and invasion in mammary epithelial cells. Proc. Natl Acad. Sci. USA 101, 1257-1262 (2004).
167. Behrens J: Cadherins and catenins: role in signal transduction and tumor progression. Cancer Meiastasis Rev. 18, 15-30 (1999).
168. Shiina H, Igawa M, Shigeno K et al.: β-catenin mutations correlate with over expression of C-myc and cyclin D1 genes in bladder cancer. J. Urol. 168, 2220-2226 (2002).
169. Fujii K, Furukawa F, Matsuyoshi N: Ligand activation of overexpressed epidermal growth factor receptor results in colony dissociation and disturbed E-cadherin function in HSC-1 human cutaneous squamous carcinoma cells. Exp. Cell Res. 223, 50-62 (1996).
170. Jones JL, Royall JE, Walker RA: E-cadherin relates to EGFR expression and lymph node metastasis in primary breast carcinoma. Br. J. Cancer 74, 1237-1241 (1996).
171. Shiozaki H, Kadowaki T, Doki Y et al.: Effect of epidermal growth factor on cadherin-mediated adhesion in a human oesophageal cancer cell line. Br. J. Cancer 71, 250-258 (1995).
172. Toyoyama H, Nuruki K, Ogawa H et al.: The reduced expression of E-cadherin, α-catenin and γ-catenin but not β-catenin in human lung cancer. Oncol. Rep. 6, 81-85 (1999).
173. Al Moustafa AE, Yansouni C, Alaoui-Jamali MA, O'Connor-McCourt M: Upregulation of E-cadherin by an anti-epidermal growth factor receptor monoclonal antibody in lung cancer cell lines. Clin. Cancer Res. 5, 681-686 (1999).
174. Al Moustafa AE, Yen L, Bentimame N, Alaoui-Jamali MA: Regulation of E-cadherin-catenin complex patterns by epidermal growth factor receptor modulation in human lung cancer cells. Lung Cancer 37, 49-56 (2002).
175. Hazan RB, Norton L: The epidermal growth factor receptor modulates the interaction of E-cadherin with the actin cytoskeleton. J. Biol. Chem. 273, 9078-9084 (1998).
176. Wilding J, Vousden KH, Soutter WP et al.: E-cadherin transfection down-regulates the epidermal growth factor receptor and reverses the invasive phenotype of human papilloma virus-transfected keratinocytes. Cancer Res. 56, 5285-5292 (1996).
177. Pegram MD, Pauletti G, Slamon DJ: HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res. Treat. 52, 65-77 (1998).
178. Brandt BH, Roetger A, Dittmar T et al.: c-erbB-2/EGFR as dominant heterodimerization partners determine a motogenic phenotype in human breast cancer cells. FASEB J. 13, 1939-1949 (1999).
179. Zhang XH, Takenaka I, Sato C, Sakamoto H: p53 and HER-2 alterations in renal cell carcinoma. Urology 50, 636-642 (1997).
180. Chausovsky A, Tsarfaty I, Kam Z et al.: Morphogenetic effects of neuregulin (neu differentiation factor) in cultured epithelial cells. Mol. Biol. Cell 9, 3195-3209 (1998).
181. Jenndahl LE, Isakson P, Baeckstrom D: c-erbB2-induced epithelial-mesenchymal transition in mammary epithelial cells is suppressed by cell-cell contact and initiated prior to E-cadherin downregulation. Int. J. Oncol. 27, 439-448 (2005).
182. Kanai Y, Ochiai A, Shibara. T et al.: c-erbB-2 gene product directly
183. Seton-Rogers SE, Brugge JS: ErbB2 and TGF-β: a cooperative role in mammary tumor progression? Cell Cycle 3, 597-600 (2004).
184. Siegel PM, Shu W, Cardiff RD, Muller WJ, Massague J: Transforming growth factor-β signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proc. Natl. Acad. Sci. USA 100, 8430-8435(2003).
185. Khoury H, Dankort DL, Sadekova S et al.: Distinct tyrosine autophosphorylation sites mediate induction of epithelial mesenchymal like transition by an activated ErbB-2/Neu receptor. Oncogene 20, 788-799 (2001).
186. Khoury H, Naujokas MA, Zuo D et al.: HGF converts ErbB2/Neu epithelial morphogenesis to cell invasion. Mol. Biol. Cell 16, 550-561 (2005).
187. Miranti CK, Brugge JS: Sensing the environment: a historical perspective on integrin signal transduction. Nat. Cell Biol. 4, E83-E90 (2002).
188. Gilcrease MZ: Integrin signaling in epithelial cells. Cancer Lett. doi: 10. 1016/;.conlet.2006.03.031 (2006) (Epub ahead of print).
189. +-dependent localization of integrin-linked kinase to cell junctions in differentiating keratinocytes. J. Biol. Chem. 278,11528-11535 (2003).
190. Hintermann E, Yang N, O'Sullivan D, Higgins JM, Quaranta V: Integrin a6β4-erbB2 complex inhibits haptotaxis by up-regulating E-cadherin cell-cell junctions in keratinocytes. J. Biol. Chem. 280, 8004-8015 (2005).
191. Al Moustafa AE, Foulkes WD, Benlimame N et al.: E6/E7 proteins of HPV type 16 and ErbB-2 cooperate to induce neoplastic transformation of primary normal oral epithelial cells. Oncogene 23, 350-358 (2004).
192. Al Moustafa AE, Foulkes WD, Wong A et al.: Cyclin D1 is essential for neoplastic transformation induced by both E6/E7 and E6/E7/ErbB-2 cooperation in normal cells. Oncogene 23, 5252-5256 (2004).
193. Woods Ignatoski KM, Dziubinski ML, Ammerman C, Ethier SP: Cooperative interactions of HER-2 and HPV-16 oncoproteins in the malignant transformation of human mammary epithelial cells. Neoplasia 7, 788-798 (2005).
194. Altundag O, Altundag K, Morandi P, Gunduz M: Adjuvant targeted therapy with trastuzumab may decrease metastatic capacity in specific group of oropharyngeal cancer patients: downregulation of E-cadherin-catenin complex by cooperative effect of erbB-2 and human papillomavirus type 16 E6/E7 protooncogenes. Med. Hypotheses 63, 277-280(2004).
195. Thomson S, Buck E, Petti F et al.: Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res. 65, 9455-9462 (2005).
196. Bremnes RM, Veve R, Gabrielson E etal.: High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small-cell lung cancer. J. Clin. Oncol. 20, 2417-2428 (2002).
197. Deeb G, Wang J, Ramnath N et al.: Altered E-cadherin and epidermal growth factor receptor expressions are associated with patient survival in lung cancer: a study utilizing high-density tissue microarray and immunohistochemistry. Mod. Pathol. 17, 430-439 (2004).
198. Hirata T, Fukuse T, Naiki H, Wada H: Expression of E-cadherin and lymph node metastasis in resected non-small-cell lung cancer. Clin. Lung Cancer 3, 134-140 (2001).
199. Liu D, Huang C, Kameyama K et al.: E-cadherin expression associated with differentiation and prognosis in patients with non-small cell lung cancer. Ann. Thorac. Surg. 71, 949-955 (2001).